DMP.DE Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 май 2024 @ 18:35):

Stats
Объем за сегодня	20 896.00
Средний объем	21 880.00
Рыночная капитализация	1.81B
EPS	€0 ( 2024-03-27 )
Дата следующего отчета о доходах	( €0 ) 2024-05-15
Last Dividend	€1.050 ( 2023-06-15 )
Next Dividend	€0 ( N/A )
P/E	27.85
ATR14	€0.0820 (0.24%)

Объем Корреляция

Длинно: 0.08 (neutral)

Кратко: -0.35 (neutral)

Signal:(55.805) Neutral

Dermapharm Holding SE Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Dermapharm Holding SE Корреляция - Валюта/Сырье

-0.29
( neutral )

-0.07
( neutral )

0.58
( weak )

-0.25
( neutral )

0.48
( neutral )

-0.77
( moderate negative )

Dermapharm Holding SE Финансовые показатели

Annual	2023
Выручка:	€1.14B
Валовая прибыль:	€342.86M (30.20 %)
EPS:	€1.160

FY	2023
Выручка:	€1.14B
Валовая прибыль:	€342.86M (30.20 %)
EPS:	€1.160

FY	2022
Выручка:	€1.02B
Валовая прибыль:	€660.83M (64.49 %)
EPS:	€2.49

FY	2021
Выручка:	€942.91M
Валовая прибыль:	€620.69M (65.83 %)
EPS:	€3.89

Financial Reports:

No articles found.

Dermapharm Holding SE Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0 (N/A)	€0 (N/A)	€0 (N/A)	€1.050 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Dermapharm Holding SE Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.49 - Stable (29.84%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€0.770	2019-06-05
Last Dividend	€1.050	2023-06-15
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	€5.67	--
Avg. Dividend % Per Year	0.00%	--
Score	3.15	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.49
Div. Directional Score	8.66	--

Next Divdend (Est)
(2025-03-31)

€0.606 Estimate 3.09 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.15

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
GRM.DE	Ex Dividend Knight	2023-07-07	Quarterly	0.00%
RNT.F	Ex Dividend Junior	2023-09-13	Annually	0.00%
BIRG.DE	Ex Dividend Junior	2023-05-11	Sporadic	0.00%
ITU.DE	Ex Dividend Knight	2023-10-06	Quarterly	0.00%
TNE5.DE	Ex Dividend Junior	2023-12-12	Semi-Annually	0.00%
CSH.DE	Ex Dividend Junior	2023-05-18	Annually	0.00%
MBB.DE	Ex Dividend Junior	2023-06-13	Annually	0.00%
WIB.DE	Ex Dividend Knight	2023-05-09	Annually	0.00%
ENI.DE	Ex Dividend Knight	2023-11-20	Semi-Annually	0.00%
OPC.DE	Ex Dividend Knight	2023-09-07	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0549	1.500	8.90	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0286	1.200	9.05	10.00	[0 - 0.3]
returnOnEquityTTM	0.114	1.500	9.84	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.598	0.800	7.01	5.61	[1 - 3]
quickRatioTTM	0.760	0.800	-0.238	-0.191	[0.8 - 2.5]
cashRatioTTM	0.402	1.500	8.88	10.00	[0.2 - 2]
debtRatioTTM	0.489	-1.500	1.855	-2.78	[0 - 0.6]
interestCoverageTTM	3.07	1.000	9.98	9.98	[3 - 30]
operatingCashFlowPerShareTTM	4.01	2.00	8.66	10.00	[0 - 30]
freeCashFlowPerShareTTM	3.24	2.00	8.38	10.00	[0 - 20]
debtEquityRatioTTM	1.979	-1.500	2.08	-3.13	[0 - 2.5]
grossProfitMarginTTM	0.543	1.000	4.28	4.28	[0.2 - 0.8]
operatingProfitMarginTTM	0.156	1.000	8.88	8.88	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.203	1.000	9.99	9.99	[0.2 - 2]
assetTurnoverTTM	0.520	0.800	9.87	7.89	[0.5 - 2]
Total Score				10.83

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	28.92	1.000	7.18	0	[1 - 100]
returnOnEquityTTM	0.114	2.50	9.90	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	3.24	2.00	8.92	10.00	[0 - 30]
dividendYielPercentageTTM	3.13	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.01	2.00	8.66	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	22.27	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.190	1.000	7.74	0	[0.1 - 0.5]
Total Score				6.49

Dermapharm Holding SE

Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.